Israeli study finds 94% drop in symptomatic COVID-19 cases with Pfizer vaccine

Reuters2021-02-15

JERUSALEM, Feb 14 (Reuters) - Israel's largest healthcare provider on Sunday reported a 94% drop in symptomatic COVID-19 infections among 600,000 people who received two doses of the Pfizer's vaccine in the country's biggest study to date.

Health maintenance organization $(HMO.AU)$ Clalit, which covers more than half of all Israelis, said the same group was also 92% less likely to develop severe illness from the virus.

The comparison was against a group of the same size, with matching medical histories, who had not received the vaccine.

"It shows unequivocally that Pfizer's coronavirus vaccine is extremely effective in the real world a week after the second dose, just as it was found to be in the clinical study," said Ran Balicer, Clalit's chief innovation officer.

He added that the data indicates the Pfizer vaccine, which was developed in partnership with Germany's BioNTech , is even more effective two weeks or more after the second shot.

Researchers at the Weizmann Institute of Science, who have been tabulating national data, said on Sunday that a sharp decline in hospitalisation and serious illness identified earlier among the first age group to be vaccinated - aged 60 or older - was seen for the first time in those aged 55 and older.

Hospitalisations and serious illness were still rising in younger groups who began vaccinations weeks later.

Israel has been conducting a rapid vaccine rollout and its database offers insights into vaccine effectiveness and at what point countries might attain herd immunity.

(Reporting by Ari Rabinovitch and Maayan Lubell Editing by David Goodman)

((ari.rabinovitch@thomsonreuters.com; +972-2-632-2202; Reuters Messaging: ari.rabinovitch@thomsonreuters.com@reuters.net))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Ericlam
    2021-02-15
    Ericlam
    Great,good to hear it is effective 
  • Lucky222
    2021-02-15
    Lucky222
    Great news. Looking forward to better 2021.
  • KTKC
    2021-02-15
    KTKC
    [鼓掌] 
  • Yanski
    2021-02-15
    Yanski
    Good to know and hope everyone in the world will be vaccinated.
Leave a comment
4